文献速递中医内科中药与中成药合理使用

当归六黄汤联合抗甲状腺药物治疗甲状腺功能亢进的系统评价与Meta分析

Efficacy and safety of Danggui Liuhuang Decoction combined with antithyroid drugs for hyperthyroidism: A systematic review and meta-analysis.
PubMed 文献 · J Ethnopharmacol · 2024-12-26

该系统评价纳入20项随机对照试验共1757例甲亢患者,比较当归六黄汤联合抗甲状腺药物与单用抗甲状腺药物。Meta分析显示联合治疗可降低FT3、FT4及中医证候积分,改善TSH水平,提高中医证候有效率,并减少不良事件,但纳入研究方法学质量普遍较低,结论需更多高质量大样本多中心RCT验证。

要点

  • 当归六黄汤联合抗甲状腺药物可改善甲亢患者甲状腺功能指标FT3、FT4及TSH。
  • 联合治疗可降低中医证候积分并提高中医证候有效率。
  • 联合治疗不良事件发生率低于单用抗甲状腺药物。

核心结论

  • 当归六黄汤联合抗甲状腺药物可能减轻甲亢患者临床症状、改善甲状腺功能并减少不良事件,临床使用似安全。
  • 因纳入研究数量和质量有限,上述结论需更多大样本、多中心、高质量RCT进一步验证。

研究设计与样本

  • 共纳入20项RCT、1757例甲亢患者,采用Cochrane偏倚风险评估工具评价质量,Revman 5.3进行Meta分析,Stata 16.0评估发表偏倚,GRADE系统评价证据确定性。

主要发现

  • 与单用抗甲状腺药物相比,联合当归六黄汤降低FT3的SMD=-0.80(95%CI:-1.31至-0.28,P=0.002)。
  • 联合治疗降低FT4的SMD=-1.47(95%CI:-1.99至-0.94,P<0.00001)。
  • 联合治疗降低中医证候积分的MD=-3.65(95%CI:-4.68至-2.62,P<0.00001)。
  • 联合治疗减少不良事件的RR=0.23(95%CI:0.15至0.36,P<0.00001)。
  • 联合治疗改善TSH水平的SMD=2.75(95%CI:1.37至4.13,P<0.0001),提高中医证候有效率的RR=1.20(95%CI:1.08至1.34,P=0.001)。

临床怎么用

  • 在甲亢患者中可考虑当归六黄汤联合抗甲状腺药物以辅助改善甲状腺功能指标和中医证候。
  • 联合治疗可能降低不良事件风险,但需结合患者个体情况并在高质量证据进一步确认前谨慎应用。

局限性

  • 纳入研究的方法学质量普遍较低。
  • 因纳入研究数量有限,复发率和生活质量评分等结局无法进行Meta分析。
  • 证据确定性经GRADE系统评价,结论需更多大样本、多中心、高质量RCT验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Hyperthyroidism is a prevalent clinical endocrine disorder. Danggui Liuhuang Decoction (DGLHD), a traditional Chinese herbal medicine formula, has shown potential benefits for patients with hyperthyroidism in recent studies. However, the clinical efficacy and safety of DGLHD have not been systematically evaluated. To address this, a systematic review and meta-analysis are necessary to comprehensively evaluate its efficacy and safety in treating hyperthyroidism. AIM OF THE STUDY: To evaluate the efficacy and safety of DGLHD in treating hyperthyroidism. MATERIALS AND METHODS: A comprehensive search of eight databases was conducted from their inception to November 2023 to identify randomized controlled trials (RCTs) comparing DGLHD combined with antithyroid drugs (ATDs) to ATDs alone. The quality of the included studies was assessed using the Cochrane Risk of Bias Assessment Tool. A meta-analysis was conducted using Revman 5.3 software, while publication bias was evaluated with Stata 16.0 software. The certainty of the evidence was assessed using the GRADE system. RESULTS: Overall, 20 RCTs involving 1757 patients with hyperthyroidism were included in this analysis. The methodological quality was generally low. The meta-analysis revealed that, compared to ATDs alone, the combination of DGLHD with ATDs was more effective in reducing free triiodothyronine (FT3) [standardized mean difference (SMD) = -0.80, 95% confidence interval (CI): -1.31 to -0.28, P = 0.002], free thyroxine (FT4) [SMD = -1.47, 95% CI: -1.99 to -0.94, P < 0.00001], Traditional Chinese Medicine (TCM) syndrome scores [mean difference (MD) = -3.65, 95% CI: -4.68 to -2.62, P < 0.00001], and adverse events [relative risk (RR) = 0.23, 95% CI: 0.15 to 0.36, P < 0.00001]. Additionally, combining DGLHD with ATDs led to an improvement in thyroid-stimulating hormone (TSH) levels [SMD = 2.75, 95% CI: 1.37 to 4.13, P < 0.0001] and increased the effectiveness rate of TCM syndrome [RR = 1.20, 95% CI: 1.08 to 1.34, P = 0.001]. However, other outcomes, such as recurrence rates and quality of life scores, could not be analyzed through meta-analysis owing to the limited number of included studies. CONCLUSION: Combining DGLHD with ATDs may alleviate clinical symptoms, enhance thyroid function, and reduce adverse events in patients with hyperthyroidism. Moreover, this treatment appears to be safe for clinical use. However, owing to the limited quantity and quality of the included studies, these conclusions require further validation through more large-sample, multicenter, high-quality RCTs.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Wei M, Jia W, Jiang Y, et al. Efficacy and safety of Danggui Liuhuang Decoction combined with antithyroid drugs for hyperthyroidism: A systematic review and meta-analysis. J Ethnopharmacol. 2024. PMID: 39732298. doi:10.1016/j.jep.2024.119253

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。